| <
Smoking habits,
a vaccine and varenicline
Five-year smoking habit survey
Charles Beck
Powerpoint
Presentation
Abstract
Smoking is one of the leading modifiable risk factors
for cardiovascular events, making it an important intervention
target. Mortality among men aged 55 to 64 is approximately
60% higher in those who smoke 20 cigarettes per day compared
to non-smokers.
Systematic review articles have been published pooling
1-year quit rates from clinical trials involving nicotine
replacement therapy (NRT) and bupropion (zyban). These
data are well accepted to be 17% and 21%, respectively.
However, longer term data is limited and conflicting with
5-year primary prevention NRT quit rates published in
the literature range from 4.7% to 20.2%.
Our research group has carried out a questionnaire study
to inform the 5-year quit rate for stop smoking therapies.
5-year smoking habit recall was recorded by a self-administered
questionnaire specifically designed to record change in
smoking behaviour. 4,000 patients in primary care at both
high and low cardio-respiratory disease risk who were
registered with a Sheffield GP were targeted by this study.
We received a response rate of 53.5%, and recorded complete
data for n = 2022 subjects. Study respondents were aged
56.0 ± 11.0 (mean ± SD), 47% male and 95%
white British ethnic origin. 13.9% of respondents were
current smokers, 36.9% ex-smokers and 49.2% never smokers.
The high (n = 1063) and low (n = 959) risk cohorts were
significantly different for age (p < 0.001) and Carstairs'
deprivation (p = 0.005), with the high-risk respondents
being older and living in more deprived areas of Sheffield.
We intend to use the results from this study to compare
the cost-effectiveness of stop smoking interventions versus
statins to prevent cardiovascular events.
Charles Beck
Academic Unit of Clinical Pharmacology,
University of Sheffield, Royal Hallamshire Hospital
c.beck@sheffield.ac.uk
| 
